Objective:To explore the medication rules and mechanism of traditional Chinese medicine（TCM） in treating patients with advanced gastric cancer through data mining technology combined with network pharmacology and gene chip technology. Methods:Medical records of 135 patients with advanced gastric cancer who benefited from TCM treatment were collected, core drug combinations were obtained by data mining technology, common targets of drugs and diseases were obtained by network pharmacology combined with gene chip technology, and relevant mechanisms of action were explored. The expression of key targets in gastric cancer and their relationship with the survival of gastric cancer were explored through Oncomine and Kaplan-Meier Plotter databases. Results:Among the 135 patients who benefited from the treatment of advanced gastric cancer,there were 81 males and 54 females, with an average age of 59.33 years. The drug frequency from high to low mainly included Huangqi（Astragalus）, Dangshen（Codonopsis）, Banxia（Pinellia）, Chenpi（Tangerine Peel）, Fuling（Poria）, and so on. The four Qi were mainly warm, flat and cold, and the five flavors were mainly sweet, bitter and pungent. The main meridian was the spleen meridian. "Huangqi（Astragalus）-Dangshen（Codonopsis）-Banxia（Pinellia）-Chenpi（Tangerine Peel）-Fuling（Poria）" was the core drug combination of 135 prescriptions, which had 77 effective active ingredients. Taking the gastric cancer samples of GSE63089 and GSE118916 datasets in GEO database as the research object, a total of 520 differential genes of gastric cancer were obtained, of which58 drugs shared common targets with gastric cancer. NTRK1, TP53, MCM2, CUL3, and CDK2 were key targets.It was found that there were significant differences in the expression of NTRK1, TP53, and MCM2 in gastric cancer and normal tissues through the Oncomine database（P＜0.05）. Through the Kaplan Meier Plotter database,it was found that the overall survival（OS） and first progression time（FP） in the high expression group of NTRK1, TP53, and MCM2 were lower than those in the low expression group, with statistically significant differences（P＜0.05）. Conclusions:The study found that the TCM prescription of advanced gastric cancer is mainly to strengthen the spleen and replenish Qi, regulate Qi and remove phlegm. The core prescription is "Huangqi（Astragalus）-Dangshen（Codonopsis）-Banxia（Pinellia）-Chenpi（Tangerine Peel）-Fuling（Poria）". It regulates key targets such as NTRK1, TP53, MCM2, CUL3, and CDK2 through active ingredients such as quercetin, isorhamnetin,kaempferol and luteolin to participate in the regulation of tumor cell cycle, inflammatory response and other processes,and plays an anti-gastric cancer role by regulating cell cycle and p53 signal pathway. NTRK1, TP53, and MCM2 are highly expressed in gastric cancer tissues. The higher the expression levels of the three, the shorter the survival time of gastric cancer patients.

李冬云教授认为,多发性骨髓瘤便秘的基本病机为正虚为本,毒瘀为标,虚实夹杂.治疗上注重整体,倡导中西医结合治疗.主张分期辨证论治,善用枳术丸临证加减,治疗前期应解毒祛瘀,顾护胃气;治疗中期应健运脾胃,以补开塞;治疗后期应滋补肝肾,增液行舟.巧用中医外治,控制并发症.同时注重日常调摄,调护情志.审证求机,组方用药,取得了较好的疗效.附验案1 则,加以佐证.

胃食管反流性咳嗽(Gastroesophageal reflux induced cough,GERC)是指胃酸及其他胃内容物反流进入食管,引起以咳嗽为突出表现的临床综合征,患者可伴或不伴烧心、反酸、嗳气等消化系统症状.因其症状反复发作,迁延不愈,严重影响患者生活质量.中医药治疗胃食管反流性咳嗽有着自身的独特优势,具体体现为理论认识基本统一,辨证论治可先于诊断性检查;治疗手段丰富,可满足临床多样化需求;可提高疗效,缩短咳嗽消失时间,减少复发等.文中通过分析中医药治疗胃食管反流性咳嗽诊治现状及存在问题,以便最大程度发挥中医药治疗胃食管反流性咳嗽的优势,可为中医、中西医结合临床治疗GERC及科研提供理论基础.

目的 分析中医药治疗功能性消化不良(FD)研究领域文献的基本信息、研究内容以及试验方案设计中存在的相关问题.方法 检索2009-2018年CNKI、万方、维普数据库收录的关于中医药治疗FD的文献.按照发表时间、作者分布区域、中医证型、中医治疗、对照组治疗、文献质量等对文献进行整理、分析并评价中医药治疗FD的临床效果.结果 (1)共检出1 214篇文献,最终纳入文献共291篇,均为随机对照试验类型文献,其中1篇Ⅰ级文献,99篇Ⅱ级文献,191篇Ⅲ级文献.(2)纳入文献中共124篇文献涉及到辨证分型,涉及到的中医证型共12种.前3位分别为脾胃气虚、肝郁脾虚、肝胃不和,占比为30.65％、25.00％和24.19％.(3)未辨证用药的文献共计204篇,其中柴胡疏肝散最常用,占文献数量的12.26％.(4)纳入文献中有62.2％的对照组采用促胃肠动力药,促胃肠动力药中,75％为多潘立酮.(5)纳入文献中仅有17篇文献涉及到观察复发率,其中16篇显示两组差异具有统计学意义(P＜0.05).(6)纳入文献中,共计83篇涉及到观察患者不良反应,中医药治疗FD的不良反应主要为口干、恶心、呕吐等.结论 中医药治疗FD文献数量呈上升趋势;中医药治疗FD临床研究存在中医证型不规范、洗脱期未严格设定、合并用药未记录等不足,未来要开展高质量临床研究,提供更为可靠的临床应用评价.